Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Sells MassArray Systems to Five Academic Institutions

NEW YORK, June 8 - Five academic research centers have purchased Sequenom's MassArray system for genotyping analysis, the company said Friday.


The University of Massachusetts Medical School, the University of Texas Health Science Center at Houston, Wake Forest University School of Medicine, and the Weizmann Institute of Science purchased MassArray systems for the first time, and Boston University School of Medicine purchased its second system, according to a statement. Sequenom, of San Diego, now has its MassArray technology installed at a total of 33 industry and academic sites.


Typically, a MassArray system costs between $400,000 and $1.1 million, depending on consumables, the company has said.


The MassArray system, first commercialized in early 2000, provides a platform for genotyping experiments without the use of fluorescence or other tagging techniques. Instead, the company's technology applies MALDI-TOF mass spectrometry directly to fragments of DNA to detect SNPs.      

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.